Want to see ES:PHM full AI Analyst Report?

Pharma Mar SA (PHM) Price & Analysis

20 Followers

PHM Stock Chart & Stats

€97.35

€0.65(0.83%)

At close: Jan 09 4:00 PM EST

€97.35

€0.65(0.83%)

Day’s Range― - ―

52-Week Range€64.00 - €105.20

Previous CloseN/A

Volume4.24K

Average Volume (3M)74.16K

Market Cap

€1.41B

Enterprise Value€1.40K

Total Cash (Recent Filing)€167.85M

Total Debt (Recent Filing)€47.54M

Price to Earnings (P/E)17.1

Beta0.68

Next Earnings

Jul 29, 2026

EPS Estimate

0.18

Next Dividend Ex-DateN/A

Dividend Yield1.26%

Share Statistics

EPS (TTM)4.65

Shares Outstanding18,000,000

10 Day Avg. Volume71,270

30 Day Avg. Volume74,161

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)5.12

Price to Sales (P/S)5.82

P/FCF Ratio29.46

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€100.00

Price Target Upside2.72% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)2.02

Revenue Forecast (FY)€205.75M

Bulls Say, Bears Say

Bulls Say

High Profit MarginsSustained high gross and net margins indicate durable pricing power and cost structure advantages in marketed oncology products and IP licensing. Strong margins improve internal funding for R&D and reduce reliance on external capital, supporting long-term strategy and reinvestment.

Improved Free Cash FlowMaterial positive FCF provides lasting financial flexibility to fund clinical programs, commercial expansion, and milestone-linked activities without immediate dilution. Reliable cash generation supports operational continuity and strengthens negotiating leverage with potential partners.

Conservative Leverage And Equity GrowthLow leverage and stronger equity position give balance sheet resilience to absorb development setbacks and invest in pipeline opportunities. Conservative debt limits refinancing risk and enhances capacity to pursue partnerships or M&A when strategic opportunities arise.

Bears Say

Revenue And Profit VolatilityHistoric swings in revenue and profitability reflect sensitivity to product launches, market uptake, and one-off events. This cyclical performance raises predictability concerns for cash flows and planning over the medium term, complicating long-range budgeting and investor visibility.

Inconsistent Cash ConversionAlthough FCF is now positive, past negative free cash flow and weak cash conversion ratios point to earnings quality and timing gaps. If R&D or commercial spend rises, the company may need external funding or to rely on partner payments, increasing financial flexibility risk.

Dependence On Clinical/regulatory MilestonesCore revenues and milestone income hinge on successful trials, approvals, and partner deals. Such dependencies create structural binary risk: delays or failures can sharply reduce revenue and licensing receipts, making multi-quarter forecasts and steady revenue progression uncertain.

Pharma Mar SA News

Pharma Mar Board Appointment Lapses, Governance Structure Unchanged

The latest update is out from Pharma Mar SA ( ($ES:PHM) ). Pharma Mar has confirmed that the...

3d ago

Pharma Mar Halts Liquidity Contract to Launch Share Buyback Program

Pharma Mar SA ( ($ES:PHM) ) has shared an update. Pharma Mar S.A. has temporarily suspended its liquidity...

18d ago

Pharma Mar Publishes Shareholder Presentation Ahead of 2026 AGM

Pharma Mar SA ( ($ES:PHM) ) has provided an update. Pharma Mar has released the presentation that its...

24d ago

Pharma Mar Shareholders Approve All Board Proposals at Ordinary Meeting

The latest update is out from Pharma Mar SA ( ($ES:PHM) ). Pharma Mar’s Ordinary General Shareholders’ Meeting,...

24d ago

Pharma Mar Declares €1.00 Tax-Free Dividend from Share Premium Reserve

Pharma Mar SA ( ($ES:PHM) ) has shared an announcement. Pharma Mar will distribute a cash dividend of...

24d ago

Pharma Mar Overhauls Board and Committees in Governance Refresh

Pharma Mar SA ( ($ES:PHM) ) just unveiled an update. Pharma Mar’s General Shareholders’ Meeting has refreshed its...

24d ago

Pharma Mar Launches €8 Million Share Buyback for Potential Corporate Deals

Pharma Mar SA ( ($ES:PHM) ) has provided an announcement. Pharma Mar’s board has approved a share buyback...

24d ago

PharmaMar’s Partner Merck Seeks Priority Approval in Japan for Zepzelca as First-Line SCLC Maintenance

Pharma Mar SA ( ($ES:PHM) ) has issued an announcement. PharmaMar said its partner Merck has filed a...

1M ago

Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan

Chardan lowered the firm’s price target on Pharma Mar (PHMMF) to EUR 100 from EUR 120 and keeps...

1M ago

EU clears PharmaMar’s Zepzelca combo for first‑line maintenance in aggressive lung cancer

Pharma Mar SA ( ($ES:PHM) ) has provided an announcement. PharmaMar has secured a key regulatory milestone after...

2M ago

Pharma Mar Calls 2026 Shareholders’ Meeting to Approve 2025 Results and Refresh Board

Pharma Mar SA ( ($ES:PHM) ) has shared an announcement. Pharma Mar S.A. has convened its Ordinary General...

2M ago

Pharma Mar initiated with a Buy at BTIG

BTIG initiated coverage of Pharma Mar (PHMMF) with a Buy rating and EUR 121 price target The current...

3M ago

Pharma Mar downgraded to Neutral from Outperform at Oddo BHF

Oddo BHF analyst Juan Ros Padilla downgraded Pharma Mar to Neutral from Outperform with a EUR 48 price...

2y ago

Pharma Mar initiated with a Buy at Chardan

Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites...

2y ago

PHM FAQ

What was Pharma Mar SA’s price range in the past 12 months?

Pharma Mar SA lowest stock price was €64.00 and its highest was €105.20 in the past 12 months.

What is Pharma Mar SA’s market cap?

Pharma Mar SA’s market cap is €1.41B.

When is Pharma Mar SA’s upcoming earnings report date?

Pharma Mar SA’s upcoming earnings report date is Jul 29, 2026 which is in 4 days.

How were Pharma Mar SA’s earnings last quarter?

Pharma Mar SA released its earnings results on Apr 23, 2026. The company reported €0.09 earnings per share for the quarter, missing the consensus estimate of €0.125 by -€0.035.

Is Pharma Mar SA overvalued?

According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharma Mar SA pay dividends?

Pharma Mar SA pays a Annually dividend of €1 which represents an annual dividend yield of 1.26%. See more information on Pharma Mar SA dividends here

What is Pharma Mar SA’s EPS estimate?

Pharma Mar SA’s EPS estimate is 0.18.

How many shares outstanding does Pharma Mar SA have?

Pharma Mar SA has 18,000,000 shares outstanding.

What happened to Pharma Mar SA’s price movement after its last earnings report?

Pharma Mar SA reported an EPS of €0.09 in its last earnings report, missing expectations of €0.125. Following the earnings report the stock price went up 3.083%.

Which hedge fund is a major shareholder of Pharma Mar SA?

Currently, no hedge funds are holding shares in ES:PHM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharma Mar SA Stock Smart Score

Neutral

Fundamentals

Return on Equity

1.26%

Trailing 12-Months

Asset Growth

23.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.

Pharma Mar SA (PHM) Earnings & Revenues

Historic Earnings Reports

PHM Stock 12 Month Forecast

Average Price Target

€100.00

▲(2.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"€71","86":"€86","101":"€101","78.5":"€78.5","93.5":"€93.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[71,78.5,86,93.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.935,76.86307692307693,78.79115384615385,80.71923076923078,82.64730769230769,84.57538461538462,86.50346153846154,88.43153846153847,90.35961538461538,92.28769230769231,94.21576923076923,96.14384615384616,98.07192307692307,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.935,76.86307692307693,78.79115384615385,80.71923076923078,82.64730769230769,84.57538461538462,86.50346153846154,88.43153846153847,90.35961538461538,92.28769230769231,94.21576923076923,96.14384615384616,98.07192307692307,{"y":100,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.935,76.86307692307693,78.79115384615385,80.71923076923078,82.64730769230769,84.57538461538462,86.50346153846154,88.43153846153847,90.35961538461538,92.28769230769231,94.21576923076923,96.14384615384616,98.07192307692307,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":78.343,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.294,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":82.986,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":93.705,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.415,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.267,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.996,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":75.675,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":82.937,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.111,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.841,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.052,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.935,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >